L
4.45
0.07 (1.60%)
Penutupan Terdahulu | 4.38 |
Buka | 4.44 |
Jumlah Dagangan | 193,219 |
Purata Dagangan (3B) | 918,959 |
Modal Pasaran | 147,703,952 |
Harga / Buku (P/B) | 2.72 |
Julat 52 Minggu | |
Tarikh Pendapatan | 11 Aug 2025 |
EPS Cair (TTM) | -3.31 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 10.67% |
Nisbah Semasa (MRQ) | 3.41 |
Aliran Tunai Operasi (OCF TTM) | -88.00 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -50.43 M |
Pulangan Atas Aset (ROA TTM) | -42.89% |
Pulangan Atas Ekuiti (ROE TTM) | -80.65% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Menurun |
Biotechnology (Global) | Bercampur | Menurun | |
Stok | Lexeo Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
0.9
Konsensus Penganalisis | 1.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | 2.0 |
Purata | 0.88 |
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment. |
|
Sektor | Healthcare |
Industri | Biotechnology |
% Dimiliki oleh Orang Dalam | 0.75% |
% Dimiliki oleh Institusi | 121.11% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 20.00 (Chardan Capital, 349.44%) | Beli |
Median | 15.00 (237.08%) | |
Rendah | 10.00 (JP Morgan, 124.72%) | Beli |
Purata | 15.00 (237.08%) | |
Jumlah | 3 Beli | |
Harga Purata @ Panggilan | 2.93 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
JP Morgan | 30 May 2025 | 10.00 (124.72%) | Beli | 2.72 |
HC Wainwright & Co. | 16 May 2025 | 15.00 (237.08%) | Beli | 3.24 |
Chardan Capital | 13 May 2025 | 20.00 (349.44%) | Beli | 2.83 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
07 Jul 2025 | Pengumuman | Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia |
24 Jun 2025 | Pengumuman | Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics |
12 May 2025 | Pengumuman | Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights |
01 May 2025 | Pengumuman | Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |